Studies have shown that certain Human papillomavirus (HPV) types are a requisite for the development of cervical cancer and other cancers of the lower genital tract. The introduction of molecular testing for HPV has facilitated the earlier detection of cervical cancer precursors and identify those women at greatest risk of future disease. Today there are multiple methods of screening for cervical precancer and clear information is needed to sort out which tests offer the greatest opportunity to assure most women that they do not have disease risk, and identify those women early at risk of current and future cervical neoplasia. This CME activity, Module 1, consists of a panel discussion exploring the availability of an FDA approved HPV test for primary, first line cervical cancer screening and how recently published interim guidance for primary screening fits with existing consensus cervical cancer screening and management guidelines. Panelists will discuss methods for testing cervical cancer, benefits of using cervical cytology and HPV testing, and integration of current screening recommendations with primary HPV testing.
This activity is intended for clinicians from a variety of specialties including obstetrics and gynecology, family medicine and, internal medicine, for residents in obstetrics/gynecology and family medicine, for advanced practice clinicians working in family planning and other community clinics, private offices and hospital settings, for pathologists who supervise residents and fellows, and for physicians with administrative responsibility for gynecology patients.
Upon completion of the course, participants will:
- Understand the epidemiology of HPV and cervical neoplasia
- Understand consensus screening and management guidelines and the new guidance for primary HPV screening and how to apply them in a clinical setting
- Understand methods and rationale for screening women under age 30
- Understand important differences between the use of specific laboratory developed testing techniques and those that have undergone intense testing and validation and achieved FDA approval and licensing.
The American Society for Colposcopy and Cervical Pathology (ASCCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Continuing Medical Education Credits
The American Society for Colposcopy and Cervical Pathology designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Many professions recognize AMA PRA Category 1 Credits™. To claim AMA CRA Category 1 Credit™ through other professions, please visit the following websites:
Edward J. Mayeaux, Jr, MD, DABFP, FAAFP
Professor and Chairman
Department of Family and Preventive Medicine
Professor of Obstetrics and Gynecology
University of South Carolina School of Medicine
Columbia, South Carolina
Warner K, Huh, MD
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Alabama, Birmingham
David C. Wilbur, MD
Director , Clinical Imaging in Pathology Massachusetts General Hospital
Professor of Pathology
Harvard Medical School
Thomas C. Wright, Jr, MD
Past President, ASCCP
Professor Emeritus of Pathology and Cell Biology
Columbia University Medical Center
New York, New York
Management of Conflicts of Interest and Contributed Funds:
As an accredited provider of CME credit, ASCCP is required to comply with the ACCME's Standards for Commercial Support and has implemented a management process to ensure that anyone in a position to affect the content of the educational activity (e.g., faculty, planners, etc.) disclosed all relevant financial relationships with a commercial interest and ensured that those relationships do not influence presentation materials. All faculty have agreed to base their presentations on best available evidence. ASCCP discloses to learners any financial relationship(s) to healthcare-related commercial interests existing within the past 12 months to include the following information:
- the name of the individual;
- the name of the commercial interest; and,
- the nature of the relationship the person has with each commercial interest.
Slides and slide notes are reviewed for possible bias prior to the activity's release by the Accreditation Committee and peer-reviewers, and potential conflicts of interest are resolved prior to the live presentation. Any discussion of off-label use of products is noted when appropriate, as is discussion of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Disclosures of these commitments and/or relationships are published in these lecture materials and provided prior to the start of the activity, so the learners may formulate their own judgments regarding the presentation(s). Under ASCCP policy, anyone declining either to disclose or amend material to eliminate potential bias identified by the Accreditation Committee will be replaced.
Author, Reviewers, and Planners' Disclosure Information:
The following are all reported disclosures of interest or potential conflicts from the 12 months preceding this activity.
- Warner K, Huh, MD, Roche (DSM); Merck & Co, Inc. (AB)
- David Wilbur, MD, VISIONGATE (C) (SH); Philips Digital (C) (F); Corista (SAB)
- Thomas C. Wright, Jr, MD, Roche (C) (SB); GenProbe/Hologics (C) (SB); Cepheid (C); Inovio (C)
Those reporting no financial relationships or conflict of interest to disclose:
- Herschel W. Lawson, MD (ASCCP Chief Medical Officer, Accreditation Committee Chair, Planner)
- Kerry O. Curtis, (ASCCP Executive Director, Planner)
- Beth C. Huff, MSN, NP (Reviewer)
- Chanise Reese-Queen (ASCCP Education Director, Planner)
- Edward J. Mayeaux, Jr, MD, DABFP, FAAFP (Author)
- Kevin Ault, MD (Reviewer)